- Report
- March 2026
- 150 Pages
United States
From €4351EUR$4,850USD£3,717GBP
- Report
- February 2026
- 150 Pages
United States
From €4351EUR$4,850USD£3,717GBP
- Report
- August 2025
- 198 Pages
Global
From €3181EUR$3,545USD£2,717GBP
€3534EUR$3,939USD£3,019GBP
- Report
- March 2026
- 150 Pages
China
From €4351EUR$4,850USD£3,717GBP
- Report
- March 2026
- 150 Pages
Canada
From €4351EUR$4,850USD£3,717GBP
- Report
- March 2026
- 150 Pages
India
From €4351EUR$4,850USD£3,717GBP
- Report
- March 2026
- 150 Pages
Germany
From €4351EUR$4,850USD£3,717GBP
- Report
- October 2024
Global
From €3140EUR$3,500USD£2,682GBP
- Report
- August 2025
Global
From €763EUR$850USD£651GBP
The Fructosamine Test is a type of In Vitro Diagnostics (IVD) test used to measure the average blood glucose levels over the past two to three weeks. It is used to monitor glycemic control in people with diabetes, and is often used in combination with other tests such as hemoglobin A1c. The test is performed by taking a blood sample and measuring the amount of fructosamine, a protein that binds to glucose, in the sample.
The Fructosamine Test market is a subset of the larger IVD market, which is estimated to be worth billions of dollars. The Fructosamine Test market is expected to grow at a steady rate due to the increasing prevalence of diabetes and the need for better glycemic control.
Some companies in the Fructosamine Test market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Ortho Clinical Diagnostics. Show Less Read more